Condition
Rectal Cancer Recurrent
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Recruiting2
Withdrawn1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07223567Phase 2Withdrawn
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
NCT07395505Enrolling By InvitationPrimary
Postoperative Results and Outcomes in Surgical Pelvic Exenteration
NCT04695782Phase 2RecruitingPrimary
Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy
NCT04288999Phase 3RecruitingPrimary
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
Showing all 4 trials